NEI
JAZZ icon

Northwest & Ethical Investments’s Jazz Pharmaceuticals JAZZ Stock Holding History

Northwest & Ethical Investments’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-500
Closed -$84.1K – 389
2018
Q3 		$84.1K Sell
500
-300
-38% -$51.6K 0.01% 336
2018
Q2 		$138K Buy
800
+100
+14% +$16.3K 0.01% 339
2018
Q1 		$106K Buy
+700
New +$103K 0.01% 341

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northwest & Ethical Investments's JAZZ Position: Q4 2018 in Review

Northwest & Ethical Investments sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2018, closing a stake of 500 shares — an estimated $84.1K sold.

Northwest & Ethical Investments first reported a position in JAZZ in Q1 2018 and held it in 3 quarters. The position peaked at $138K in Q2 2018. 417 funds tracked by Wall St. Rank hold JAZZ as of Q4 2018.

  • Northwest & Ethical Investments reported no remaining Jazz Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Northwest & Ethical Investments sold 500 Jazz Pharmaceuticals shares in Q4 2018, an estimated $84.1K.
  • Northwest & Ethical Investments first reported a position in Jazz Pharmaceuticals in Q1 2018 and held it in 3 quarters.
  • Northwest & Ethical Investments's Jazz Pharmaceuticals position peaked at $138K in Q2 2018.
  • 417 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2018.

Based on Northwest & Ethical Investments's 13F filing for Q4 2018, filed 8 Jul 2025.